Madrigal Pharmaceuticals, Inc.
MDGL
$305.61
-$4.91-1.58%
| Weiss Ratings | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.52 | |||
| Price History | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.79% | |||
| 30-Day Total Return | -1.25% | |||
| 60-Day Total Return | -9.83% | |||
| 90-Day Total Return | -11.46% | |||
| Year to Date Total Return | -2.60% | |||
| 1-Year Total Return | 22.91% | |||
| 2-Year Total Return | 24.57% | |||
| 3-Year Total Return | 240.02% | |||
| 5-Year Total Return | 361.65% | |||
| 52-Week High % Change | -17.73% | |||
| 52-Week Low % Change | 64.30% | |||
| Price | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $377.46 | |||
| 52-Week Low Price | $189.00 | |||
| 52-Week Low Price (Date) | Apr 26, 2024 | |||
| 52-Week High Price (Date) | Feb 26, 2025 | |||
| Valuation | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.86B | |||
| Enterprise Value | 6.05B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -22.11 | |||
| Earnings Per Share Growth | 10.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 37.80 | |||
| Price/Book (Q) | 9.06 | |||
| Enterprise Value/Revenue (TTM) | 33.58 | |||
| Price | $305.61 | |||
| Enterprise Value/EBITDA (TTM) | -12.18 | |||
| Enterprise Value/EBIT | -12.15 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 21.93M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 267 824 2827 | |||
| Address | Four Tower Bridge West Conshohocken, PA 19428 | |||
| Website | www.madrigalpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -276.39% | |||
| Profit Margin | -258.63% | |||
| Management Effectiveness | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -36.98% | |||
| Return on Equity | -- | |||
| Income Statement | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 180.13M | |||
| Total Revenue (TTM) | 180.13M | |||
| Revenue Per Share | $8.21 | |||
| Gross Profit (TTM) | 173.90M | |||
| EBITDA (TTM) | -496.78M | |||
| EBIT (TTM) | -497.87M | |||
| Net Income (TTM) | -465.89M | |||
| Net Income Avl. to Common (TTM) | -465.89M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 47.04% | |||
| EPS Diluted (TTM) | -22.11 | |||
| EPS Diluted Growth (Q YOY) | 52.28% | |||
| Balance Sheet | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 926.25M | |||
| Cash Per Share (Q) | $42.24 | |||
| Total Current Assets (Q) | 1.03B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 754.38M | |||
| Current Ratio (Q) | 6.102 | |||
| Book Value Per Share (Q) | $34.28 | |||
| Total Assets (Q) | 1.04B | |||
| Total Current Liabilities (Q) | 169.28M | |||
| Total Debt (Q) | 119.57M | |||
| Total Liabilities (Q) | 287.86M | |||
| Total Common Equity (Q) | 754.38M | |||
| Cash Flow | MDGL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -274.39M | |||
| Cash from Financing (TTM) | 735.06M | |||
| Net Change in Cash (TTM) | 5.10M | |||
| Levered Free Cash Flow (TTM) | -296.99M | |||
| Cash from Operations (TTM) | -455.57M | |||
